MGNX - Why MacroGenics Stock Jumped Today
Shares of MacroGenics (NASDAQ: MGNX) had jumped 5.3% as of 3:09 p.m. EST on Monday. The gain came after the company announced results from a late-stage study of Margenza as a third-line treatment for metastatic HER2-positive breast cancer. These results were published in the Journal of the American Medical Association Oncology .
MacroGenics stated that Margenza met the primary endpoint of the phase 3 study with a 24% progression-free survival relative risk reduction versus Roche 's Herceptin. Both Margenza and Herceptin were administered along with chemotherapy.
Image source: Getty Images.
For further details see:
Why MacroGenics Stock Jumped Today